{"nctId":"NCT01776424","briefTitle":"Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease","startDateStruct":{"date":"2013-02-28","type":"ACTUAL"},"conditions":["Prevention & Control"],"count":27395,"armGroups":[{"label":"Rivaroxaban 2.5mg + Aspirin 100mg","type":"EXPERIMENTAL","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)","Drug: Aspirin","Drug: Pantoprazole","Drug: Pantoprazole placebo"]},{"label":"Rivaroxaban 5mg + Aspirin Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Rivaroxaban (Xarelto, BAY59-7939)","Drug: Aspirin placebo","Drug: Pantoprazole","Drug: Pantoprazole placebo"]},{"label":"Rivaroxaban Placebo + Aspirin 100mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aspirin","Drug: Rivaroxaban placebo","Drug: Pantoprazole","Drug: Pantoprazole placebo"]}],"interventions":[{"name":"Rivaroxaban (Xarelto, BAY59-7939)","otherNames":[]},{"name":"Rivaroxaban (Xarelto, BAY59-7939)","otherNames":[]},{"name":"Aspirin","otherNames":[]},{"name":"Aspirin placebo","otherNames":[]},{"name":"Rivaroxaban placebo","otherNames":[]},{"name":"Pantoprazole","otherNames":[]},{"name":"Pantoprazole placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Meet criteria for CAD and/or PAD\n\nSubjects with CAD must also meet at least one of the following criteria:\n\n* Age â‰¥65, or\n* Age \\<65 and documented atherosclerosis or revascularization involving at least 2 vascular beds, or at least 2 additional risk factors\n\nExclusion Criteria:\n\n* Stroke within 1 month or any history of hemorrhagic or lacunar stroke\n* Severe heart failure with known ejection fraction \\<30% or New York Heart Association (NYHA) class III or IV symptoms\n* Estimated glomerular filtration rate (eGFR)\\<15 mL/min\n* Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death","description":"Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"379","spread":null},{"groupId":"OG001","value":"448","spread":null},{"groupId":"OG002","value":"496","spread":null}]}]}]},{"type":"PRIMARY","title":"The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria","description":"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).\n\nCount of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"288","spread":null},{"groupId":"OG001","value":"255","spread":null},{"groupId":"OG002","value":"170","spread":null}]}]}]},{"type":"SECONDARY","title":"The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death","description":"Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"329","spread":null},{"groupId":"OG001","value":"397","spread":null},{"groupId":"OG002","value":"450","spread":null}]}]}]},{"type":"SECONDARY","title":"The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death","description":"Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":null},{"groupId":"OG001","value":"453","spread":null},{"groupId":"OG002","value":"516","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality","description":"Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"313","spread":null},{"groupId":"OG001","value":"366","spread":null},{"groupId":"OG002","value":"378","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part","description":"Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"353","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part","description":"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).\n\nCount of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"All-cause Mortality in LTOLE Part","description":"Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"282","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":692,"n":9134},"commonTop":["Nasopharyngitis","Diarrhoea","Epistaxis","Contusion","Back pain"]}}}